KCNMB4
MOLECULAR TARGETpotassium calcium-activated channel subfamily M regulatory beta subunit 4
KCNMB4 (potassium calcium-activated channel subfamily M regulatory beta subunit 4) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KCNMB4
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Thyroxine | 1.10 | 2 |
| 2 | Resveratrol | 1.10 | 2 |
| 3 | Carvedilol | 1.10 | 2 |
| 4 | Ethylestrenol | 1.10 | 2 |
| 5 | Ezetimibe | 1.10 | 2 |
| 6 | Glyburide | 1.10 | 2 |
| 7 | Latanoprost | 1.10 | 2 |
| 8 | Nicardipine | 1.10 | 2 |
| 9 | Nisoldipine | 1.10 | 2 |
| 10 | Norethindrone Acetate Acetate ester of norethindrone that is used as | 1.10 | 2 |
| 11 | Perphenazine | 1.10 | 2 |
| 12 | Thioridazine | 1.10 | 2 |
| 13 | Thyroxine | 1.10 | 2 |
| 14 | pterostilbene | 0.69 | 1 |
| 15 | Fluocinolone Acetonide | 0.69 | 1 |
| 16 | Methyltestosterone | 0.69 | 1 |
| 17 | nafadotride | 0.69 | 1 |
| 18 | Nateglinide | 0.69 | 1 |
| 19 | 3',4'-didemethylnobiletin [Supplementary Concept] | 0.69 | 1 |
| 20 | Nortriptyline | 0.69 | 1 |
| 21 | Promethazine | 0.69 | 1 |
| 22 | Ritonavir | 0.69 | 1 |
About KCNMB4 as a Drug Target
KCNMB4 (potassium calcium-activated channel subfamily M regulatory beta subunit 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented KCNMB4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KCNMB4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.